The TRS technology platform has broad clinical applicability and offers the potential for the development of novel product lines addressing multiple market segments. In order to fully capitalize on all of these product opportunities, TRS has chosen to pursue a corporate partnership business model whereby TRS partners with established medical, dental and 3D printing companies to develop products of interest to them. Once cleared by the FDA, the partner commercializes the product and TRS is the manufacturer.

TRS has experienced strong interest in our technology platform from prospective partners and several partnership projects are underway.

Johnson & Johnson Innovation Catalyzes New and Exciting Science and Technology in Pharmaceutical, Medical Device, Diagnostic and Consumer Healthcare Spaces

— Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheiner's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections —

Materialise and Tissue Regeneration Systems Announce Partnership to Manufacture 3D-Printed Tracheal Splints